Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease

被引:34
作者
Horowitz, Mia [1 ]
Braunstein, Hila [1 ]
Zimran, Ari [2 ,3 ]
Revel-Vilk, Shoshana [2 ,3 ]
Goker-Alpan, Ozlem [4 ]
机构
[1] Tel Aviv Univ, Schmunis Sch Biomed & Canc Res, IL-69978 Tel Aviv, Israel
[2] Shaare Zedek Med Ctr, Gaucher Unit, Jerusalem, Israel
[3] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
[4] Lysosomal & Rare Disorders Res & Treatment Ctr LD, Fairfax, VA USA
关键词
Gaucher disease; Glucocerebrosidase (GCase); Parkinson disease; Misfolding; Unfolded Protein Response (UPR); UNFOLDED PROTEIN RESPONSE; SPHINGOLIPID ACTIVATOR PROTEINS; HUMAN GLUCOCEREBROSIDASE GENE; ENZYME REPLACEMENT THERAPY; ALPHA-SYNUCLEIN; ENDOPLASMIC-RETICULUM; BETA-GLUCOSIDASE; GBA MUTATIONS; RECOMBINANT GLUCOCEREBROSIDASE; SUBSTANTIA-NIGRA;
D O I
10.1016/j.addr.2022.114402
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Lysosomes have a critical role in maintaining normal cellular homeostasis mediated by their involvement in secretion, plasma membrane repair, cell signaling and energy metabolism. Lysosomal storage disorders (LSDs) are a group of approximately 50 rare disorders caused by lysosomal dysfunction that occur due to mutations in a gene of a lysosomal protein. Gaucher disease (GD), an autosomal recessive disorder and one of the most common LSDs, is caused by the deficiency of the lysosomal enzyme acid-beta-glucocerebrosidase (GCase), due to biallelic mutations in the GBA1 gene. Reduced GCase activity leads to the accumulation of glucosylceramide (GlcCer), which is deacylated by lysosomal acid ceramidase to a toxic metabolite, glucosylshpingosine (GlcSph). Most GBA1 variants are recognized as misfolded in the ER, where the retention for refolding attempts initiates stress and activates the stress response known as the Unfolded Protein Response (UPR). The distinct clinical subtypes of GD are based on whether there is primary involvement of the central nervous system. Type 1 GD (GD1) is the nonneuropathic type, however, the recent recognition of the association of GD with the development of parkinsonism defies this classification. Patients with GD1 and carriers of GBA1 mutations are at risk for the development of parkinsonian manifestations. Parkinson disease (PD), the second most prevalent neurodegenerative disease, culminates in a movement disorder with the premature death of the patients. In PD and related disorders, collectively called synucleinopathies, the hallmark pathology is a-synuclein positive aggregates referred to as Lewy bodies or Lewy neurites and the death of dopaminergic neurons. While PD is mostly sporadic, in similar to 5-10% of cases, the disease results from pathogenic variants in a growing number of genes. The most common genetic cause of PD is mutations in GBA1. Two mechanisms have been proposed for this link: (A) a "gain of function" mechanism, in which mutant GCase (protein) contributes to aggregate formation and to the development of PD, and the (B) "haploinsufficiency" ("loss of function") model, suggesting that one normal GBA1 allele is insufficient to carry adequate GCase activity and functional deficiency of GCase impedes a-synuclein metabolism. Lysosomal dysfunction, compromised autophagy and mitophagy further enhance the accumulation of a-synuclein, which results in the development of PD pathology. The present review will elaborate on the biology of GD, its association with PD and related disorders, and discuss the possible mechanisms underlying this association. (c) 2022 Elsevier B.V. All rights reserved.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines.
    Toshi Nagatsu
    Makoto Sawada
    Cellular and Molecular Neurobiology, 2006, 26 (4) : 781 - 802
  • [32] Cellular and molecular pathophysiology in the progression of Parkinson's disease
    Zaman, Vandana
    Shields, Donald C.
    Shams, Ramsha
    Drasites, Kelsey P.
    Matzelle, Denise
    Haque, Azizul
    Banik, Narendra L.
    METABOLIC BRAIN DISEASE, 2021, 36 (05) : 815 - 827
  • [33] Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease
    Stojkovska, Iva
    Krainc, Dimitri
    Mazzulli, Joseph R.
    CELL AND TISSUE RESEARCH, 2018, 373 (01) : 51 - 60
  • [34] Exploring the Pathogenetic Mechanisms underlying Parkinson's Disease in Medaka Fish
    Matsui, Hideaki
    Uemura, Norihito
    Yamakado, Hodaka
    Takeda, Shunichi
    Takahashi, Ryosuke
    JOURNAL OF PARKINSONS DISEASE, 2014, 4 (02) : 301 - 310
  • [35] Melatonin and Parkinson Disease: Current Status and Future Perspectives for Molecular Mechanisms
    Tamtaji, Omid Reza
    Reiter, Russel J.
    Alipoor, Reza
    Dadgostar, Ehsan
    Kouchaki, Ebrahim
    Asemi, Zatollah
    CELLULAR AND MOLECULAR NEUROBIOLOGY, 2020, 40 (01) : 15 - 23
  • [36] Cell biology of Parkinson's disease: Mechanisms of synaptic, lysosomal, and mitochondrial dysfunction
    Brooker, Sarah M.
    Naylor, Grace E.
    Krainc, Dimitri
    CURRENT OPINION IN NEUROBIOLOGY, 2024, 85
  • [37] Molecular Mechanisms of Glutamate Toxicity in Parkinson's Disease
    Wang, Ji
    Wang, Fushun
    Mai, Dongmei
    Qu, Shaogang
    FRONTIERS IN NEUROSCIENCE, 2020, 14
  • [38] Molecular evidence of impaired iron metabolism and its association with Parkinson's disease progression
    Haitao Chi
    Wei Tang
    Ying Bai
    3 Biotech, 2020, 10
  • [39] Dissecting the potential molecular mechanisms underlying a-synuclein cell-to-cell transfer in Parkinson's disease
    Angot, Elodie
    Brundin, Patrik
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S143 - S147
  • [40] Molecular evidence of impaired iron metabolism and its association with Parkinson's disease progression
    Chi, Haitao
    Tang, Wei
    Bai, Ying
    3 BIOTECH, 2020, 10 (04)